TibaRay’s Cancer Technology: Protected by 21 Issued and Pending Patents

With more than $30 million raised to date, TibaRay moves toward broader commercial applications

SILICON VALLEY, CA, UNITED STATES, August 27, 2026 /EINPresswire.com/ -- TibaRay, a medical technology company born from research at Stanford University, is building on more than three decades of scientific development as it expands the commercial foundation for its new class of cancer treatment technology. At the center of that growth is Galactica™, TibaRay’s proprietary linear accelerator platform designed to deliver radiotherapy faster and with greater precision than the legacy equipment representing today’s state-of-the-art.

TibaRay has assembled and built a robust intellectual property portfolio of 21 issued and pending patents, including exclusively licensed Stanford/SLAC technology and TibaRay-owned intellectual property. The company has also raised more than $30 million to advance its technology, including $13 million in non-dilutive grants. Together, these milestones show how far the technology has come and how TibaRay is moving it closer to commercial deployment.

“The technology proof-of-concept at Stanford University was a milestone in itself, so to see decades of development validated through a strong patent estate and commercial agreements tells us we are going in the right direction,” said Thinh Tran, CEO of TibaRay. “Care teams and patients need radiotherapy that works faster and does less damage to healthy tissue. That's the demand we built Galactica to meet, and these milestones show we're delivering on it."

As previously announced, TibaRay began initial manufacturing of the first phase of Galactica systems for integration with its partner, Leo Cancer Care, marking an early step toward commercialization and the company's long-term mission of Curing Cancer in a FLASH™.

“I’ve spent my career as both a physician-scientist at Stanford University and a researcher pushing radiation therapy innovations, so I understand that it takes a village to move an idea from the lab to a patient,” said Bill Loo, MD, PhD, Co-Founder and Chief Medical Advisor of TibaRay. “Each milestone TibaRay reaches shows the work born at Stanford University is holding up to real-world challenges, and it gives us confidence in where the technology is headed.”

More broadly, TibaRay’s growth also highlights a shift in radiation oncology, as hospital systems increasingly seek more efficient solutions to the limitations of the most advanced equipment today. Leo Cancer Care’s Grace system featuring the breakthrough performance of TibaRay’s Galactica is primed to meet that demand, designed to be an upright radiotherapy platform that treats patients sitting or standing rather than lying down, shortening treatment sessions while improving comfort in a device smaller than current systems on the market. The platform also lays the foundation for FLASH, an emerging technique that delivers radiation in a fraction of a second. Cancer radiotherapy and radiobiology experts believe this speed has the potential to reduce damage to surrounding healthy tissue, which is a benefit that sets Galactica apart as it moves toward clinical deployment.

TibaRay's path from lab to market represents a model for turning fundamental research into real-world impact. From decades of research to a robust intellectual property portfolio, more than $30 million raised, commercial collaborations and systems now entering manufacturing, TibaRay’s progress reflects the continued evolution of technology beyond the lab. As the company moves closer to clinical deployment, TibaRay's progress offers a new kind of innovation story, one grounded in a steadfast mission to make faster, more precise cancer treatment accessible to patients everywhere.

Individuals interested in supporting TibaRay’s continued growth can learn more about its current investment opportunity by visiting Wefunder.com/TibaRay.

###

About TibaRay

TibaRay, headquartered in Fremont, California, is a medical technology company advancing innovative linear accelerator technology for radiotherapy and other commercial applications. The company’s next-generation accelerator platform is designed to help physicians deliver radiotherapy with greater precision, speed, and efficiency, while also supporting broader uses of compact, high-performance linear accelerators beyond cancer care.

Founded on technology spun out from Stanford University, TibaRay brings together expertise in physics, engineering, and medicine to advance the future of radiation technology. TibaRay is driven by its mission of Curing Cancer in a FLASH™. To learn more, visit TibaRay.com.

###

Karla Nafarrate
InnoVision Marketing Group
email us here